logo-loader
viewNetscientific PLC

NetScientific PLC - Board Changes

RNS Number : 8662W
NetScientific PLC
13 December 2019
 

 

 

NetScientific plc

("NetScientific" or the "Company")

 

Board Changes

 

 

London, UK - 13 December 2019 - NetScientific plc (AIM: NSCI), the transatlantic healthcare IP commercialisation Group, today announces planned changes to its Board of Directors. Barry Wilson will retire from the Board following seven years as Non-Executive Director. John Clarkson joins NetScientific as Non-Executive Director with immediate effect.

 

John brings more than twenty years of commercial expertise in leadership roles including that of CEO, Chairman and Non-Executive Director. He was previously partner in charge of a consultancy division in Cooper Deloitte (now PricewaterhouseCoopers), providing services to a range of blue-chip companies and was subsequently Vice Chairman of Laura Ashley Inc. John is an active investor in start-ups, high-tech and growing businesses.

 

John holds a MBA from Cranfield University, after qualifying as an accountant and is a fellow of the Association of Chartered Certified Accountants.

 

John Eric Clarkson (aged 70) currently holds or has held in the past 5 years the following directorships and partnerships:

Current directorships

Past directorships & partnerships

Heimdall Protective Tech Ltd

Recycling Technologies Ltd

Revival Car Hire Ltd


Wrens Cathedral Ltd


Fox Brothers (Elswick) Ltd


C & C Developments Fleetwood Ltd


Around Town @ Limited


C & C Property Developments Ltd


Development Financial and Management Services Limited


 

In addition, Mr. Clarkson was until 31 July 2019 a director of Wroxall Abbey Estate Limited, which was put in to administration on 22 October 2019. The process of administration is ongoing and the sale of assets of the Company is not finalised, and consequently the level of unsatisfied creditors is currently unknown.

 

No further disclosure is required under Paragraph (g) to Schedule Two of the AIM Rules for Companies.

 

Sir Richard Sykes, Chairman of NetScientific, said: "We would like to thank Barry for his significant contributions to the Company.  He has provided great strategic insight and direction during his time on the Board and we wish him well for his future. At the same time, we are delighted to welcome John to NetScientific.  His commercial experience will be extremely valuable as the Company continues to drive value for its shareholders."

 

#  #  #

 

For more information, please contact:

 

  NetScientific

  Ian Postlethwaite, CEO / CFO

Tel: +44 (0)20 3514 1800

WHIreland (NOMAD, Financial Adviser and Broker)

Chris Fielding / Darshan Patel

Tel: +44 (0)20 7220 1666

MO PR ADVISORY (Press Contact)

Mo Noonan

Tel: +44 (0)78 7644 4977

 

 

About NetScientific

NetScientific PLC is a transatlantic healthcare IP commercialisation Group focused on technologies and companies that have the potential to treat chronic disease and significantly improve the health and well-being of people. 

 

For more information, please visit the website at www.NetScientific.net


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
BOATJBJTMBBBBRL

Quick facts: Netscientific PLC

Price: 2.5

Market: AIM
Market Cap: £1.96 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: ANGLE reports positive data from Parsortix FDA clinical study

Top stories from the Proactive Investors UK newsroom: ANGLE PLC (LON:AGL) has received positive results from its Parsortix FDA clinical study for metastatic breast cancer. The 400-subject clinical study will support an application for Class II regulatory clearance for Parsortix in the...

on 31/5/19